Extraordinary claims require extraordinary evidence

Journal of Health Economics

Volumn 24, Issue 5, 2005, Pages 1030-1033

  Light, Donald W ^a,b   Warburton, Rebecca N ^c   DiMasi, Joseph A ^d   Hansen, Ronald W ^e   Grabowski, Henry G ^f  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF VICTORIA   (Canada)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ROCHESTER   (United States)

^f DUKE UNIVERSITY   (United States)

Author keywords

Bias 1, 253 ; External validity; Internal validity; Pharmaceutical industry; R D cost

Indexed keywords

CONFIDENTIALITY; COST BENEFIT ANALYSIS; DRUG COST; DRUG FORMULATION; DRUG INDUSTRY; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH ECONOMICS; HEALTH SURVEY; MEDICAL RESEARCH; NOTE; TAX; VALIDATION PROCESS;

EID: 23944447912     PISSN: 01676296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhealeco.2005.07.001     Document Type: Note

References (0)